Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial

No deterioration in patient-reported outcome scores for health-related quality of life, physical functioning, and symptoms was observed with enfortumab vedotin therapy among patients with locally advanced/metastatic urothelial carcinoma previously treated with platinum-containing chemotherapy and PD-1/PD-L1 inhibitor therapy.